| Description |
This study was a single-arm, single-center, open-label clinical study to evaluate the safety and efficacy of GC012F in high-risk, transplantation-eligible NDMM patients. The study was planned to include 20 evaluable subjects. A total of two cycles of induction therapy (bortezomib-based three-drug regimen, with details determined by the investigator on the basis of the patient) were selectively administered before or after collection in eligible subjects. Participants will then receive a single GC012F infusion, with response assessments at 1 month, 3 months, and every 3 months thereafter for 2 years until the end of the trial (each response assessment will require MRD testing). |
